Skip to main content
Top

29-01-2025 | Gastric Cancer | Original Article

Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody–drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer

Authors: Wenpeng Huang, Liming Li, Yuhan Zhou, Qi Yang, Jason C. Mixdorf, Todd E. Barnhart, Jessica C. Hsu, Rachel J. Saladin, Chihao Liu, Zachary T. Rosenkrans, Jonathan W. Engle, Jianbo Gao, Lei Kang, Weibo Cai

Published in: European Journal of Nuclear Medicine and Molecular Imaging

Login to get access

Abstract

Purpose

Trophoblast cell-surface antigen 2 (Trop2) is overexpressed in various solid tumors and contributes to tumor progression, while its expression remains low in normal tissues. Trop2-targeting antibody–drug conjugate (ADC), sacituzumab govitecan-hziy (Trodelvy), has shown efficacy in targeting this antigen. Leveraging the enhanced specificity of ADCs, we conducted the first immunoPET imaging study of Trop2 expression in gastric cancer (GC) and triple-negative breast cancer (TNBC) models using 89Zr-labeled Trodelvy ([89Zr]Zr-DFO-Trodelvy). This approach enables preclinical screening to identify patients who may benefit from targeted therapies.

Materials and methods

Trop2 expression levels in GC and TNBC cell lines (NCI-N87, HGC-27, MDST8, and MDA-MB-468) were assessed via flow cytometry and immunofluorescence staining. Labeling of DFO-Trodelvy with 89Zr was performed in Na2CO3 buffer at pH 7 (37 °C, 1.5 h). In vitro stability was analyzed using radio-thin layer chromatography. Biological properties were evaluated through cell uptake, saturation binding assays, and biodistribution experiments. ImmunoPET imaging with [89Zr]Zr-DFO-Trodelvy was performed at various time points to confirm its in vivo targeting. Immunohistochemical and immunofluorescence analyses were conducted on tumor tissues from tumor-bearing mice.

Results

The radiochemical yield of [89Zr]Zr-DFO-Trodelvy exceeded 90%, with a radiochemical purity (RCP) greater than 99%. Trop2 expression was high in MDA-MB-468 and NCI-N87 cells, while it was low in MDST8 and HGC-27 cells. The KD values of [89Zr]Zr-DFO-Trodelvy were 9.44 nM for MDA-MB-468 and 3.51 nM for NCI-N87 cells. ImmunoPET imaging with [89Zr]Zr-DFO-Trodelvy provided clear visualization of tumor morphology in MDA-MB-468 and NCI-N87 models (n = 3) as early as 6 h post-injection. Tumor uptake of [89Zr]Zr-DFO-Trodelvy increased over time, peaking at 48 h (MDA-MB-468: 10.03 ± 1.26%ID/g; NCI-N87: 14.30 ± 2.09%ID/g), and was significantly higher than in the MDST8 (5.27 ± 0.71%ID/g) and HGC-27 (4.37 ± 0.54%ID/g) models. Co-injection with 2 mg of unlabeled Trodelvy significantly reduced uptake in NCI-N87 and MDA-MB-468 tumors (P < 0.001). A high target-to-non-target ratio was observed at 48 h, showing specific tumor uptake and minimal off-target accumulation. Fluorescence imaging further confirmed higher tumor uptake in the IRDye800CW-Trodelvy group compared to the IRDye800CW-Trodelvy-blocking group (P < 0.001).

Conclusions

[89Zr]Zr-DFO-Trodelvy for immunoPET imaging in TNBC and GC tumor models demonstrated specific, rapid, and sustained accumulation in tumors with high Trop2 expression, allowing for noninvasive monitoring of Trop2 status. The increased tumor-to-background ratio observed in immunoPET imaging suggests strong potential for clinical translation. Additionally, optical imaging, with its superior spatial resolution compared to PET, was employed to aid in precise probe localization and potentially enhancing differentiation between healthy and malignant tissues during surgical procedures.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:167–92.CrossRefPubMed Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:167–92.CrossRefPubMed
2.
go back to reference Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer J Clin. 2023;73:17–48. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer J Clin. 2023;73:17–48.
4.
go back to reference Li C, Kang L, Fan K, Ferreira CA, Becker KV, Huo N, et al. ImmunoPET of CD146 in orthotopic and metastatic breast cancer models. Bioconjug Chem. 2021;32:1306–14.CrossRefPubMedPubMedCentral Li C, Kang L, Fan K, Ferreira CA, Becker KV, Huo N, et al. ImmunoPET of CD146 in orthotopic and metastatic breast cancer models. Bioconjug Chem. 2021;32:1306–14.CrossRefPubMedPubMedCentral
5.
go back to reference Lütje S, Rijpkema M, Helfrich W, Oyen WJG, Boerman OC. Targeted radionuclide and fluorescence dual-modality imaging of cancer: preclinical advances and clinical translation. Mol Imaging Biol. 2014;16:747–55.CrossRefPubMed Lütje S, Rijpkema M, Helfrich W, Oyen WJG, Boerman OC. Targeted radionuclide and fluorescence dual-modality imaging of cancer: preclinical advances and clinical translation. Mol Imaging Biol. 2014;16:747–55.CrossRefPubMed
6.
go back to reference Khessib T, Jha P, Davidzon GA, Iagaru A, Shah J. Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review. Semin Nucl Med. 2024;54:270–92.CrossRefPubMed Khessib T, Jha P, Davidzon GA, Iagaru A, Shah J. Nuclear Medicine and Molecular Imaging Applications in Gynecologic Malignancies: A Comprehensive Review. Semin Nucl Med. 2024;54:270–92.CrossRefPubMed
7.
go back to reference Wang X-Y, Yang F, Jin C, Fu D-L. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol. 2014;20:15580–9.CrossRefPubMedPubMedCentral Wang X-Y, Yang F, Jin C, Fu D-L. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol. 2014;20:15580–9.CrossRefPubMedPubMedCentral
8.
go back to reference Liu X, Li J, Deng J, Zhao J, Zhao G, Zhang T, et al. Targeting Trop2 in solid tumors: a look into structures and novel epitopes. Front Immunol. 2023;14:1332489.CrossRefPubMedPubMedCentral Liu X, Li J, Deng J, Zhao J, Zhao G, Zhang T, et al. Targeting Trop2 in solid tumors: a look into structures and novel epitopes. Front Immunol. 2023;14:1332489.CrossRefPubMedPubMedCentral
9.
go back to reference Wen Y, Ouyang D, Zou Q, Chen Q, Luo N, He H, et al. A literature review of the promising future of TROP2: a potential drug therapy target. Ann Transl Med. 2022;10:1403.CrossRefPubMedPubMedCentral Wen Y, Ouyang D, Zou Q, Chen Q, Luo N, He H, et al. A literature review of the promising future of TROP2: a potential drug therapy target. Ann Transl Med. 2022;10:1403.CrossRefPubMedPubMedCentral
10.
go back to reference De Moura A, Loirat D, Vaillant S, Korbi S, Kiavue N, Bello Roufai D, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. 2024;31:572–80.CrossRefPubMed De Moura A, Loirat D, Vaillant S, Korbi S, Kiavue N, Bello Roufai D, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer patients treated at Institut Curie Hospitals: efficacy, safety, and impact of brain metastases. Breast Cancer. 2024;31:572–80.CrossRefPubMed
11.
go back to reference Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741–51.CrossRefPubMed Bardia A, Mayer IA, Vahdat LT, Tolaney SM, Isakoff SJ, Diamond JR, et al. Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer. N Engl J Med. 2019;380:741–51.CrossRefPubMed
12.
go back to reference Huang W, Liang C, Zhang Y, Zhang D, An S, Wu Q, et al. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers. Eur J Nucl Med Mol Imaging. 2024;51:380–94.CrossRefPubMed Huang W, Liang C, Zhang Y, Zhang D, An S, Wu Q, et al. ImmunoPET imaging of Trop2 expression in solid tumors with nanobody tracers. Eur J Nucl Med Mol Imaging. 2024;51:380–94.CrossRefPubMed
13.
go back to reference Shao F, Pan Z, Long Y, Zhu Z, Wang K, Ji H, et al. Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer. J Nanobiotechnology. 2022;20:243.CrossRefPubMedPubMedCentral Shao F, Pan Z, Long Y, Zhu Z, Wang K, Ji H, et al. Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer. J Nanobiotechnology. 2022;20:243.CrossRefPubMedPubMedCentral
15.
go back to reference Kang L, Jiang D, England CG, Barnhart TE, Yu B, Rosenkrans ZT, et al. ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab. Eur J Nucl Med Mol Imaging. 2018;45:1372–81.CrossRefPubMedPubMedCentral Kang L, Jiang D, England CG, Barnhart TE, Yu B, Rosenkrans ZT, et al. ImmunoPET imaging of CD38 in murine lymphoma models using 89Zr-labeled daratumumab. Eur J Nucl Med Mol Imaging. 2018;45:1372–81.CrossRefPubMedPubMedCentral
16.
go back to reference Huang W, Wang T, Qiu Y, Li C, Chen B, Song L, et al. CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies. Eur J Nucl Med Mol Imaging. 2024. Huang W, Wang T, Qiu Y, Li C, Chen B, Song L, et al. CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies. Eur J Nucl Med Mol Imaging. 2024.
17.
go back to reference Chen Z, Yang Q, Song L, Qiu Y, Wang T, Wu S, et al. Enhanced Theranostic Efficacy of 89Zr and 177Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice. Mol Pharm. 2024. Chen Z, Yang Q, Song L, Qiu Y, Wang T, Wu S, et al. Enhanced Theranostic Efficacy of 89Zr and 177Lu-Labeled Aflibercept in Renal Cancer: A Viable Option for Clinical Practice. Mol Pharm. 2024.
18.
go back to reference Yang Q, Chen Z, Qiu Y, Huang W, Wang T, Song L, et al. Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer. Eur J Nucl Med Mol Imaging. 2024;51:1246–60.CrossRefPubMed Yang Q, Chen Z, Qiu Y, Huang W, Wang T, Song L, et al. Theranostic role of 89Zr- and 177Lu-labeled aflibercept in breast cancer. Eur J Nucl Med Mol Imaging. 2024;51:1246–60.CrossRefPubMed
19.
go back to reference Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMed Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–7.PubMed
20.
go back to reference Valentin J. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37:1–332.PubMed Valentin J. The 2007 Recommendations of the International Commission on Radiological Protection. ICRP publication 103. Ann ICRP. 2007;37:1–332.PubMed
21.
go back to reference Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989–9006.CrossRefPubMedPubMedCentral Goldenberg DM, Stein R, Sharkey RM. The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9:28989–9006.CrossRefPubMedPubMedCentral
22.
go back to reference Soubra A, Gencturk M, Froelich J, Balaji P, Gupta S, Jha G, et al. FDG-PET/CT for assessing the response to neoadjuvant chemotherapy in bladder cancer patients. Clin Genitourin Cancer. 2018;16:360–4.CrossRefPubMed Soubra A, Gencturk M, Froelich J, Balaji P, Gupta S, Jha G, et al. FDG-PET/CT for assessing the response to neoadjuvant chemotherapy in bladder cancer patients. Clin Genitourin Cancer. 2018;16:360–4.CrossRefPubMed
23.
go back to reference Salas JR, Clark PM. Signaling Pathways That Drive 18F-FDG Accumulation in Cancer. J Nucl Med. 2022;63:659–63.CrossRefPubMed Salas JR, Clark PM. Signaling Pathways That Drive 18F-FDG Accumulation in Cancer. J Nucl Med. 2022;63:659–63.CrossRefPubMed
24.
go back to reference Kang L, Li C, Rosenkrans ZT, Engle JW, Wang R, Jiang D, et al. Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab’)2 Fragments of Obinutuzumab in Lymphoma. J Nucl Med. 2021;62:372–8.CrossRefPubMedPubMedCentral Kang L, Li C, Rosenkrans ZT, Engle JW, Wang R, Jiang D, et al. Noninvasive Evaluation of CD20 Expression Using 64Cu-Labeled F(ab’)2 Fragments of Obinutuzumab in Lymphoma. J Nucl Med. 2021;62:372–8.CrossRefPubMedPubMedCentral
25.
go back to reference Chen W, Li M, Younis MH, Barnhart TE, Jiang D, Sun T, et al. ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49:861–70.CrossRefPubMed Chen W, Li M, Younis MH, Barnhart TE, Jiang D, Sun T, et al. ImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49:861–70.CrossRefPubMed
26.
go back to reference Li C, Liu J, Yang X, Yang Q, Huang W, Zhang M, et al. Theranostic application of 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models. Eur J Nucl Med Mol Imaging. 2022;50:168–83.CrossRefPubMed Li C, Liu J, Yang X, Yang Q, Huang W, Zhang M, et al. Theranostic application of 64Cu/177Lu-labeled anti-Trop2 monoclonal antibody in pancreatic cancer tumor models. Eur J Nucl Med Mol Imaging. 2022;50:168–83.CrossRefPubMed
Metadata
Title
Preclinical evaluation of zirconium-89 labeled anti-Trop2 antibody–drug conjugate (Trodelvy) for imaging in gastric cancer and triple-negative breast cancer
Authors
Wenpeng Huang
Liming Li
Yuhan Zhou
Qi Yang
Jason C. Mixdorf
Todd E. Barnhart
Jessica C. Hsu
Rachel J. Saladin
Chihao Liu
Zachary T. Rosenkrans
Jonathan W. Engle
Jianbo Gao
Lei Kang
Weibo Cai
Publication date
29-01-2025
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-025-07106-4